New Amsterdam Sciences Overview

  • Founded
  • 2012
  • Status
  • Out of Business
  • Latest Deal Type
  • Out of Business

New Amsterdam Sciences General Information


Developer of anti-idiopathic pulmonary fibrosis drug created for the treatment of influenza infection, solid tumors and wound healing. The company's activities are engaged in the research, development and licensing of small molecule antioxidant SOD mimetics and peptide analogues for treatment of idiopathic pulmonary fibrosis, influenza infection, wound healing and solid tumors

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly Angel backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • 14362 North Frank Lloyd Wright Boulevard
  • Suite 1000
  • Scottsdale, AZ 85260
  • United States
+1 (480) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

New Amsterdam Sciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Out of Business 22-Mar-2020 Completed Out of Business
2. Angel (individual) 19-Nov-2015 00000 Completed Startup
1. Grant 11-Mar-2014 Completed Startup
To view New Amsterdam Sciences’s complete valuation and funding history, request access »

New Amsterdam Sciences Patents

New Amsterdam Sciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20170065663-A1 Substance and method for treating influenza Abandoned 02-May-2014 0000000000